CO5271678A1 - COMPOSITIONS TO FACILITATE SKIN GROWTH AND METHODS AND ARTICLES THAT USE THEM - Google Patents

COMPOSITIONS TO FACILITATE SKIN GROWTH AND METHODS AND ARTICLES THAT USE THEM

Info

Publication number
CO5271678A1
CO5271678A1 CO00080126A CO00080126A CO5271678A1 CO 5271678 A1 CO5271678 A1 CO 5271678A1 CO 00080126 A CO00080126 A CO 00080126A CO 00080126 A CO00080126 A CO 00080126A CO 5271678 A1 CO5271678 A1 CO 5271678A1
Authority
CO
Colombia
Prior art keywords
therapeutically effective
skin
pharmaceutically acceptable
acceptable derivative
growth
Prior art date
Application number
CO00080126A
Other languages
Spanish (es)
Inventor
Marvin S Antelman
Original Assignee
Marantech Holding Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/552,172 external-priority patent/US6258385B1/en
Application filed by Marantech Holding Llc filed Critical Marantech Holding Llc
Publication of CO5271678A1 publication Critical patent/CO5271678A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/12—Face or body powders for grooming, adorning or absorbing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G3/00—Compounds of copper
    • C01G3/02—Oxides; Hydroxides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Una composición farmacéutica que comprende una cantidad terapéuticamente efectiva de tetróxido de tetraplata o un derivado farmacéuticamente aceptable de éste, intrínsecamente libre de persulfato añadido.Un método para prevenir, tratar o abordar una o más enfermedades dermatológicas de la piel del paciente, que comprenden la administración, a la piel, de tetróxido, o un derivado de éste farmacéuticamente aceptable, que esté esencialmente libre de persulfato, añadido en cantidades y durante un lapso terapéuticamente efectivo para tratar esta enfermedad o estas enfermedades.1Un método para facilitar o aumentar el crecimiento de la piel del paciente, el cual comprende la administración de al menos un compuesto electrónicamente activo, o un derivado farmacéuticamente aceptable de éste, que tenga al menos dos cationes polivalentes, uno de los cuales tenga al menos un segundo estado de valencia diferente, para abordar o tratar la enfermedad, o un síntoma de ella, en una cantidad y por un período que sea terapéuticamente efectivo para facilitar el crecimiento aumentado de la piel.2 Una composición que promueva el crecimiento de la piel que comprenda una cantidad terapéuticamente efectiva de al menos un compuesto electrónicamente activo, o un derivado farmacéuticamente aceptable de éste, que tenga al menos dos cationes polivalentes, al menos uno de los cuales tenga un primer estado de valencia y al menos uno de los cuales un segundo estado de valencia diferente, para tratar o abordar la enfermedad, o un síntoma de ésta, en una cantidad tal y por un período tal que resulte terapéuticamente efectiva como para facilitar o incrementar el crecimiento de la piel.A pharmaceutical composition comprising a therapeutically effective amount of tetraplate tetroxide or a pharmaceutically acceptable derivative thereof, intrinsically free of added persulfate. A method of preventing, treating or addressing one or more dermatological diseases of the patient's skin, which comprise administration. , to the skin, of tetroxide, or a pharmaceutically acceptable derivative thereof, which is essentially free of persulfate, added in amounts and for a therapeutically effective period to treat this disease or these diseases.1 A method to facilitate or increase the growth of the The patient's skin, which comprises the administration of at least one electronically active compound, or a pharmaceutically acceptable derivative thereof, having at least two polyvalent cations, one of which has at least a second different valence state, to address or treat the disease, or a symptom of it, in u at an amount and for a period that is therapeutically effective to facilitate increased skin growth.2 A composition that promotes skin growth that comprises a therapeutically effective amount of at least one electronically active compound, or a pharmaceutically acceptable derivative thereof , that has at least two polyvalent cations, at least one of which has a first state of valence and at least one of which a second state of different valence, to treat or address the disease, or a symptom of it, in a amount such and for a period that is therapeutically effective to facilitate or increase skin growth.

CO00080126A 2000-01-06 2000-10-20 COMPOSITIONS TO FACILITATE SKIN GROWTH AND METHODS AND ARTICLES THAT USE THEM CO5271678A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17479300P 2000-01-06 2000-01-06
US18405300P 2000-02-22 2000-02-22
US09/552,172 US6258385B1 (en) 1999-04-22 2000-04-18 Tetrasilver tetroxide treatment for skin conditions
US21450300P 2000-06-28 2000-06-28

Publications (1)

Publication Number Publication Date
CO5271678A1 true CO5271678A1 (en) 2003-04-30

Family

ID=40458508

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00080126A CO5271678A1 (en) 2000-01-06 2000-10-20 COMPOSITIONS TO FACILITATE SKIN GROWTH AND METHODS AND ARTICLES THAT USE THEM

Country Status (8)

Country Link
EP (3) EP1246630A4 (en)
JP (3) JP2003519187A (en)
AR (1) AR029184A1 (en)
AU (3) AU784593B2 (en)
CO (1) CO5271678A1 (en)
GT (1) GT200000184A (en)
TW (1) TWI235661B (en)
WO (3) WO2001049303A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US7635488B2 (en) 2001-03-13 2009-12-22 Dbv Technologies Patches and uses thereof
JP2004529929A (en) * 2001-04-23 2004-09-30 ニュクリスト ファーマシューティカルズ コーポレーション Use of metals for induction of apoptosis and inhibition of matrix metalloproteinases
TWI274585B (en) * 2002-06-03 2007-03-01 Nat Health Research Institutes Pharmaceutical composition, kit, and packaged product for treating infection by a flaviviridae virus
MXPA05010172A (en) * 2003-03-24 2005-11-08 Wellstat Biologics Corp Newcastle disease virus administration.
US8048870B2 (en) * 2005-01-11 2011-11-01 Batarseh Kareem I Apoptosis-inducing antineoplastic silver (I) coordination complexes
ES2872962T3 (en) * 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronophthalides for therapeutic use
CN106008571A (en) 2005-12-30 2016-10-12 安纳考尔医药公司 Boron-containing small molecules
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
KR101622870B1 (en) 2006-02-16 2016-05-19 아나코르 파마슈티칼스 인코포레이티드 Boron-containing small molecules as anti-inflammatory agents
DE102006023394A1 (en) * 2006-05-17 2007-11-22 Gerd Prof. Wengler Preparation and use of an antiviral chemotherapeutic agent which affects a host cell to block the replication of viruses in the cell
GB0714670D0 (en) 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
FR2924349B1 (en) 2007-12-03 2010-01-01 Dbv Tech ALLERGEN DISENSIBILITY METHOD
FR2924350B1 (en) 2007-12-03 2010-08-13 Dbv Tech METHOD AND COMPOSITIONS FOR SKIN VACCINATION
WO2009085651A1 (en) 2007-12-20 2009-07-09 Nucryst Pharmaceuticals Corp. Metal carbonate particles for use in medicine and methods of making thereof
MX2010009765A (en) 2008-03-06 2013-07-12 Anacor Pharmaceuticals Inc Boron-containing small molecules as anti-inflammatory agents.
JP5505679B2 (en) * 2008-07-04 2014-05-28 和宏 小川 Treatment or prevention of protozoan infections
WO2010028005A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
GB2472126B (en) * 2009-07-21 2011-08-03 Aidance Skincare & Topical Solutions Llc Topical Formulations Containing Silver (II) Oxide and Zinc Oxide
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
WO2011019618A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US9346834B2 (en) 2009-10-20 2016-05-24 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US8461134B2 (en) 2009-11-11 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP5570006B2 (en) 2009-12-24 2014-08-13 国立大学法人 東京大学 Virus inactivating agent
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
US8623911B2 (en) 2010-03-19 2014-01-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
CN103140228A (en) 2010-09-07 2013-06-05 阿纳科制药公司 Benzoxaborole derivatives for treating bacterial infections
CN103338641B (en) * 2010-12-22 2015-11-25 国立大学法人东京大学 Via
JP5824704B1 (en) * 2014-07-20 2015-11-25 株式会社ライラック研究所 Powder-like stagnation agent
WO2016125132A1 (en) * 2015-02-08 2016-08-11 Argaman Technologies Ltd. Antimicrobial material comprising synergistic combinations of metal oxides
US11224227B2 (en) 2015-02-08 2022-01-18 Argaman Technologies Ltd. Antimicrobial material comprising synergistic combinations of metal oxides
JP6775927B2 (en) * 2015-08-27 2020-10-28 住化エンバイロメンタルサイエンス株式会社 Antibacterial composition
EP3269357A1 (en) * 2016-07-15 2018-01-17 Universiteit Gent Particles comprising metals and/or metal oxides for use to transform compounds in vivo

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2199459B1 (en) * 1972-09-20 1975-08-08 Agronomique Inst Nat Rech
FR2245351A2 (en) * 1973-09-27 1975-04-25 Agronomique Inst Nat Rech Injectable trace element compns - as suspensions in oil for treating trace element deficiencies in animals
DK313381A (en) * 1980-07-24 1982-01-25 Mckechnike Chemicals Ltd REGULATED TRANSMISSION RELEASE
US4574782A (en) * 1981-11-16 1986-03-11 Corning Glass Works Radio frequency-induced hyperthermia for tumor therapy
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
US4994014A (en) * 1988-07-26 1991-02-19 Gordon Robert T Process for treating diseased cells including the step of raising the subjects blood oxygen level
US5612019A (en) * 1988-12-19 1997-03-18 Gordon, Deceased; David Diagnosis and treatment of HIV viral infection using magnetic metal transferrin particles
JPH0525051A (en) * 1991-07-19 1993-02-02 Meiji Seika Kaisha Ltd Anemia-preventive/therapeutic agent
US5336499A (en) * 1992-01-10 1994-08-09 Antelman Technologies, Ltd. Molecular crystal device for pharmaceuticals
ATE191086T1 (en) * 1994-07-27 2000-04-15 Pilgrimm Herbert SUPERPARAMAGNETIC PARTICLES, METHOD FOR THE PRODUCTION AND USE THEREOF
US5676977A (en) * 1994-09-22 1997-10-14 Antelman Technologies Ltd. Method of curing AIDS with tetrasilver tetroxide molecular crystal devices
JPH0912415A (en) * 1995-06-29 1997-01-14 Sekisui Chem Co Ltd Antibacterial composition and antibacterial and bactericidal treatment
DE19600744A1 (en) * 1996-01-11 1997-07-17 Werner Alois Prof Dipl Kaiser Magnetic substance for local hyperthermic treatment of mainly small tumors
DE19624426A1 (en) * 1996-06-19 1998-01-02 Christian Bergemann Magnetic particle for transport of diagnostic or therapeutic agent
JPH10218779A (en) * 1997-02-10 1998-08-18 Nippon Electric Glass Co Ltd Hyperthermic material
DE19716732C2 (en) * 1997-03-07 1999-03-25 Max Delbrueck Centrum Specific magnetosomes, processes for their preparation and their use
JP2000060976A (en) * 1998-08-21 2000-02-29 Hiroaki Koyanagi Skin contact body used in skin contact with effective spot and route contining to spot of human body

Also Published As

Publication number Publication date
AU784593B2 (en) 2006-05-11
WO2001049301A1 (en) 2001-07-12
EP1250142A1 (en) 2002-10-23
AU784597B2 (en) 2006-05-11
EP1246629A1 (en) 2002-10-09
AU1435901A (en) 2001-07-16
AU1339601A (en) 2001-07-16
JP2003519187A (en) 2003-06-17
EP1246630A4 (en) 2007-04-18
EP1250142A4 (en) 2007-07-11
JP2003519188A (en) 2003-06-17
AU1222201A (en) 2001-07-16
WO2001049303A1 (en) 2001-07-12
AR029184A1 (en) 2003-06-18
TWI235661B (en) 2005-07-11
WO2001049302A1 (en) 2001-07-12
EP1246630A1 (en) 2002-10-09
JP2003519189A (en) 2003-06-17
GT200000184A (en) 2002-04-16
EP1246629A4 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
CO5271678A1 (en) COMPOSITIONS TO FACILITATE SKIN GROWTH AND METHODS AND ARTICLES THAT USE THEM
UY26635A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
BRPI0011640B8 (en) oligosaccharide aldonic acids and their topical use
PT1175214E (en) COMPOSITIONS OF CYCLE-OXYGENASE-2 INHIBITOR WITH A QUICK START OF ITS THERAPEUTIC EFFECT
BR0107732A (en) Method to prevent or treat a disease
BR0312286A (en) 2 'and 3' prodrugs - modified nucleoside for treatment of flaviviridae infections
BR0314236A (en) Oligonucleotide formulation, pharmaceutical composition, kit, antiviral compound, preparation of oligonucleotide and methods for selection of an antiviral oligonucleotide for use as an antiviral agent, for prophylaxis or treatment of a viral infection in a patient, for prophylactic treatment of cancer caused by oncoviruses. for identifying a compound that alters the binding of an oligonucleotide to at least one viral component, for purifying oligonucleotide binding to at least one viral component and for enriching oligonucleotides from an oligonucleotide cluster
AR013506A1 (en) USE OF A PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO BE USED IN THE TREATMENT OF DISEASES OF PULMONARCHRONIC OBSTRUCTION AND OF A KIT INCLUDING FORMOTEROL OR A SALT OR SOLVATE OF THE SAME AND BUDESONIDE
AR058359A1 (en) COMBINATIONS
BR0208984A (en) fatty acids, glycerides and medium chain length analogues as factors for survival and neutrophil activation
AR039164A1 (en) VENLAFAXINE SALTS OF LOW WATER SOLUBILITY
DK1392329T3 (en) Use of sulodexide for the treatment of inflammatory bowel disease
AR040248A1 (en) PHARMACO FOR THE TREATMENT OF HYPERACTIVE BLADDER
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
ATE257704T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING NORASTEMIZOLE.
CO5190674A1 (en) TREATMENT OF NEUROTIC DISORDERS NEUROTIC DISORDERS
AR012731A1 (en) USE OF A TAXANE DERIVATIVE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, USE OF A BIODICABILITY IMPROVEMENT AGENT OF SUCH A DERIVATIVE ORAL DOSAGE FORM AND UNDERSTANDING ITEM AND METHOD FOR FORMING A BIO-AVAILABLE ACTIVE AGENT.
BRPI0409699A (en) methods of inducing the diuretic effect, inducing, maintaining or restoring the diuretic effect of a non-adenosine modifying diuretic, maintaining, restoring or improving renal function in a patient, inducing diuresis, preventing the onset of renal impairment in a patient with fluid or CHF overload, treating CHF patients and improving overall health outcomes, pharmaceutical composition and uses
AR045263A1 (en) METHOD, KIT AND PHARMACEUTICAL COMPOSITION TO TREAT VIRAL INFECTIONS
BRPI0410374A (en) pharmaceutical composition comprising valsartan
BR0315609A (en) Method of treating, preventing, modifying or controlling pain and pharmaceutical composition
AR022338A1 (en) A BENZAMIDE COMPOUND, A MEDICINAL PRODUCT CONTAINING IT, AND USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF A DIGESTIVE DISEASE OR TO IMPROVE THE MOBILITY OF THE GASTROINTESTINAL TRACT.
AR002957A1 (en) A COMBINATION OF USEFUL COMPOUNDS, THEIR USE TO PREPARE A MEDICINAL PRODUCT, AND A PHARMACEUTICAL COMPOSITION AND COMBINATION THAT CONTAIN THEM.
BR0212744A (en) Cisplatin formulations of reduced toxicity and methods for their use
AR045070A1 (en) PREPARED PHARMACEUTICAL TOPICS OF ASCORBIC ACID WITH POST-ANTIMICOTIC EFFECT